Celldex Therapeutics reported $29.95M in Current Liabilities for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Liabilities Change
Agenus AGEN:US $ 159.72M 3.34M
Amgen AMGN:US $ 12618M 268M
Applied Genetic Technologies AGTC:US $ 25.21M 0.6M
Aptinyx Inc APTX:US $ 5.68M 945K
Biocept BIOC:US $ 14.1M 2.32M
Bristol Myers Squibb BMY:US $ 20915M 1906M
Celldex Therapeutics CLDX:US $ 29.95M 15.39M
Cytrx CYTR:US 3.1M 633.56K
Glaxosmithkline GSK:US $ 37835M 13557M
Immunogen IMGN:US $ 87.07M 2.95M
Merrimack Pharmaceuticals MACK:US $ 441K 123K
Nektar Therapeutics NKTR:US $ 104.98M 0.3M
Newlink Genetics NLNK:US $ 4.83M 0.41M
Northwest Biotherapeutics NWBO:US 98.16M 31.85M
Rigel Pharmaceuticals RIGL:US $ 54.96M 4.27M
Seattle Genetics SGEN:US $ 608.52M 77.23M